---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-079669"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-05-31T23:59:38.407085+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM

## Summary
- Initial June 27 meeting lacked quorum; adjourned to June 28.
- All nine ordinary resolutions passed, including re-election of five directors.
- Ratified BDO USA as independent auditor and Haysmacintyre as statutory auditor.
- Non-binding advisory vote favored annual frequency for say-on-pay.
- Votes in favor ranged from 5.7B to 6.5B of ~15.8B outstanding shares.

## SEC filing metadata
- accession: 0000950170-24-079669
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/0000950170-24-079669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/aktx-20240628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-079669
- JSON: https://secwatch.observer/filing/0000950170-24-079669.json
- Plain text: https://secwatch.observer/filing/0000950170-24-079669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.